πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

2,562 results for β€œCancer” Clear

  1. A trial to learn how safe AZD5335 is and if a drug called itraconazole changes how AZD5335 moves through the body over time in adults with ovarian, peritoneal, or fallopian tube cancer

    AstraZeneca AB

    Ovarian cancer Primary peritoneal cancer Fallopian tube cancer

    phase 1 other active

    1 trial

  2. A trial to learn if AZD5335 alone and in combination with other treatments is safe and effective and how it moves through the body in people with solid tumors

    AstraZeneca AB

    Platinum-resistant recurrent (PRR) ovarian cancer, Platinum-sensitive recurrent (PSR) ovarian cancer, Lung Adenocarcinoma, and endometrial cancer.

    phase 1 other active

    1 trial

  3. A trial to learn if AZD9829 is safe and works alone and in combination with other treatments for participants with certain blood cancers.

    AstraZeneca AB

    CD123-Positive Hematological Malignancies: Module 1 focuses on R/R Acute Myeloid Leukemia and R/R Myelodysplastic Syndrome.

    phase 1 other active

    1 trial

  4. AB598

    Arcus Biosciences

    Advanced Cancer

    phase 1 small molecule active

    1 trial

  5. AB680

    Arcus Biosciences

    Advanced Pancreatic Cancer

    phase 1 small molecule active

    1 trial

  6. AB801

    Arcus Biosciences

    Advanced Cancer

    phase 1 small molecule active

    1 trial

  7. AB801

    Arcus Biosciences

    Cancer

    phase 1 small molecule completed

    1 trial

  8. ADCT-301

    ADC Therapeutics SA

    Head and Neck Cancer Squamous Cell Carcinoma

    phase 1 small molecule terminated

    1 trial

  9. ADCT-502

    ADC Therapeutics SA

    Breast Cancer

    phase 1 small molecule terminated

    1 trial

  10. ADME: A Study to Understand What the Body does to the Study Compound Called PF-07220060 When Taken by Healthy Adults.

    Pfizer Australia Pty Ltd

    metastatic/advanced breast cancer

    phase 1 other active

    1 trial

  11. ALX2004

    ALX ONCOLOGY HOLDINGS INC

    NSCLC (Advanced Non-small Cell Lung Cancer)

    phase 1 small molecule active

    1 trial

  12. AMG 193 in Combination with Other Therapies in Subjects with Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous MTAP-deletion – Master Protocol

    Amgen

    Gastrointestinal tract, biliary tract, or pancreatic cancers with homozygous methylthioadenosine phosphorylase (MTAP)-deletion

    phase 1 other active

    1 trial

  13. AMG 509

    BEONE MEDICINES AUS PTY LTD

    Prostate Cancer

    phase 1 small molecule active

    1 trial

  14. APL-1202 and APL-1501 (Single ascending dose)

    Jian Li

    Bladder Cancer

    phase 1 small molecule active

    1 trial

  15. ARISE with AR

    BRIGHT MINDS BIOSCIENCES INC.

    Pediatric Cancer

    phase 1 other active

    1 trial

  16. ASTX660

    United Therapeutics Europe Ltd

    Advanced Cancer

    phase 1 small molecule active

    1 trial

  17. AU-011

    Aura Biosciences

    Non-muscle-invasive Bladder Cancer

    phase 1 small molecule active

    1 trial

  18. AZD2014 3 on/4 off & weekly paclitaxel

    United Therapeutics Europe Ltd

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  19. AZD3514

    AstraZeneca

    Prostate Cancer

    phase 1 small molecule completed

    1 trial

  20. AZD7762

    AstraZeneca

    Cancer

    phase 1 small molecule terminated

    1 trial

  21. Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

    Eli Lilly Co.

    Prostatic Neoplasms

    phase 1 other active

    1 trial

  22. Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell

    CytoMed Therapeutics Ltd

    Colorectal Cancer

    phase 1 mab active

    1 trial

  23. Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted Ξ³Ξ΄ T Cells (CTM-N2D)

    CytoMed Therapeutics Ltd

    Cancer

    phase 1 mab active

    1 trial

  24. An Open-Label Multicenter Phase 1b Study of Tolinapant (ASTX660) in Combination With Radiotherapy/Chemoradiotherapy (RT/CRT) in Preoperative Treatment of Patients With Rectum Cancer (PRAAR 1: Preoperative Radiotherapy And ASTX660 in Rectum Cancer)

    The George Institute

    Neoadjuvant therapy in locally-advanced rectal cancer

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources